Type 2 Diabetes Mellitus

Metabolic Diseases
181
Pipeline Programs
30
Companies
50
Clinical Trials
1 recruiting
36
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
35
2
25
3
48
68
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2652%
Peptide
2448%
+ 133 programs with unclassified modality

On Market (36)

Approved therapies currently available

U
ACARBOSEApproved
acarbose
Unknown Company
alpha-Glucosidase Inhibitor [EPC]oral2012
Sanofi
ADLYXINApproved
lixisenatide
Sanofi
subcutaneous2016
U
AFREZZAApproved
insulin human
Unknown Company
Insulin [EPC]inhalation2014
Sanofi
AMARYLApproved
glimepiride
Sanofi
oral1995
U
ASPRUZYO SPRINKLEApproved
ranolazine
Unknown Company
Anti-anginal [EPC]oral2022
AstraZeneca
BYETTAApproved
exenatide
AstraZeneca
GLP-1 Receptor Agonist [EPC]subcutaneous2005
U
COLESEVELAM HYDROCHLORIDEApproved
colesevelam
Unknown Company
oral2019
U
EXENATIDE SYNTHETICApproved
exenatide
Unknown Company
GLP-1 Receptor Agonist [EPC]subcutaneous2024
AstraZeneca
FARXIGAApproved
dapagliflozin
AstraZeneca
oral2014
U
GLIMEPIRIDEApproved
glimepiride
Unknown Company
Sulfonylurea [EPC]oral2009
M&
JANUVIAApproved
sitagliptin
Merck & Co.
oral2006
Sanofi
LANTUSApproved
insulin glargine
Sanofi
Insulin Analog [EPC]injection2000
Sanofi
LANTUS SOLOSTARApproved
insulin glargine
Sanofi
Insulin Analog [EPC]injection2000
U
LINAGLIPTINApproved
linagliptin
Unknown Company
oral2025
Eli Lilly and Company
MOUNJAROApproved
tirzepatide
Eli Lilly and Company
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]subcutaneous2022
Eli Lilly and Company
MOUNJARO (AUTOINJECTOR)Approved
tirzepatide
Eli Lilly and Company
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]subcutaneous2022
Eli Lilly and Company
MOUNJARO KWIKPENApproved
tirzepatide
Eli Lilly and Company
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]subcutaneous2022
U
NATEGLINIDEApproved
nateglinide
Unknown Company
Glinide [EPC]oral2018
Takeda
NESINAApproved
alogliptin
Takeda
oral2013
Novo Nordisk
NOVOLOG MIX 70/30Approved
insulin aspart
Novo Nordisk
Insulin Analog [EPC]subcutaneous2001
Novo Nordisk
NOVOLOG MIX 70/30 FLEXPENApproved
insulin aspart
Novo Nordisk
Insulin Analog [EPC]subcutaneous2001
Novo Nordisk
NOVOLOG MIX 70/30 PENFILLApproved
insulin aspart
Novo Nordisk
Insulin Analog [EPC]subcutaneous2001
Bayer
PRECOSEApproved
acarbose
Bayer
oral1995
U
RANOLAZINEApproved
ranolazine
Unknown Company
oral2023
U
SAXAGLIPTINApproved
saxagliptin
Unknown Company
oral2023
Novo Nordisk
SAXENDAApproved
liraglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2014
U
SITAGLIPTINApproved
sitagliptin phosphate
Unknown Company
film coated
U
SITAGLIPTIN PHOSPHATEApproved
sitagliptin phosphate
Unknown Company
oral
Sanofi
TOUJEO MAX SOLOSTARApproved
insulin glargine
Sanofi
Insulin Analog [EPC]subcutaneous2015
Sanofi
TOUJEO SOLOSTARApproved
insulin glargine
Sanofi
Insulin Analog [EPC]subcutaneous2015
Boehringer Ingelheim
TRADJENTAApproved
linagliptin
Boehringer Ingelheim
Dipeptidyl Peptidase 4 Inhibitor [EPC]oral2011
Novo Nordisk
VICTOZAApproved
liraglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2010
Eli Lilly and Company
ZEPBOUNDApproved
tirzepatide
Eli Lilly and Company
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]subcutaneous2023
Eli Lilly and Company
ZEPBOUND (AUTOINJECTOR)Approved
tirzepatide
Eli Lilly and Company
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]subcutaneous2023
Eli Lilly and Company
ZEPBOUND KWIKPENApproved
tirzepatide
Eli Lilly and Company
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]subcutaneous2023
U
ZITUVIOApproved
sitagliptin
Unknown Company
Dipeptidyl Peptidase 4 Inhibitor [EPC]oral2023

Competitive Landscape

36 companies ranked by most advanced pipeline stage

Novo Nordisk
20 programs
2
4
8
InsulatardPhase 41 trial
Insulin Degludec 100 UNT/ML [Tresiba]Phase 41 trial
LiraglutidePhase 4Peptide1 trial
LiraglutidePhase 4Peptide1 trial
LiraglutidePhase 4Peptide1 trial
+15 more programs
Active Trials
NCT00497133Completed20Est. Mar 2008
NCT02982408Completed48Est. Mar 2019
NCT07121114Completed1,500Est. Jul 2025
+15 more trials
M&
Merck & Co.RAHWAY, NJ
19 programs
5
1
9
1
SitagliptinPhase 4Small Molecule1 trial
Ertugliflozin 5 mgPhase 3
Ertugliflozin 5 mgPhase 3
MK0478Phase 31 trial
Metformin on top of intensive insulin therapyPhase 31 trial
+14 more programs
Active Trials
NCT00923962Completed35Est. Jan 2012
NCT02194608Completed500Est. Jul 2013
NCT01278485Completed726Est. Jun 2012
+16 more trials
Sanofi
SanofiPARIS, France
19 programs
2
1
10
5
GlimepiridePhase 41 trial
INSULIN GLARGINE HOE 901Phase 41 trial
LANTUS(Insulin glargine)Phase 45 trials
TofogliflozinPhase 4Small Molecule1 trial
insulin humanPhase 41 trial
+14 more programs
Active Trials
NCT02663245Completed564Est. Dec 2018
NCT03437720Withdrawn0Est. Aug 2021
NCT03376802Completed24Est. Dec 2018
+24 more trials
Astellas
AstellasChina - Shenyang
14 programs
2
1
7
3
IpragliflozinPhase 4Small Molecule1 trial
Oral administration of IpragliflozinPhase 4Small Molecule1 trial
metforminPhase 41 trial
ASP1941Phase 31 trial
IpragliflozinPhase 3Small Molecule1 trial
+9 more programs
Active Trials
NCT00769275Completed1,123Est. Jan 2008
NCT01023945Completed30Est. Mar 2010
NCT01302145Completed36Est. Dec 2009
+15 more trials
DS
13 programs
3
3
4
1
High-dose colesevelamPhase 41 trial
ColesevelamPhase 32 trials
Metformin HCl and Colesevelam PlaceboPhase 31 trial
Rivoglitazone HClPhase 31 trial
WelcholPhase 31 trial
+8 more programs
Active Trials
NCT00476710Completed36Est. Apr 2009
NCT02669732Completed21Est. Oct 2016
NCT02004678Completed40Est. Oct 2013
+11 more trials
AstraZeneca
12 programs
2
3
1
insulin glarginePhase 41 trial
AC2993Phase 31 trial
DapagliflozinPhase 3Small Molecule1 trial
exenatidePhase 3Peptide
AZD8329Phase 11 trial
+7 more programs
Active Trials
NCT02226822Completed1,869Est. Feb 2019
NCT02322762Completed15,992Est. Aug 2019
NCT02200627Completed1,724Est. Apr 2016
+8 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
10 programs
3
5
2
Insulin Analog Mid MixturePhase 41 trial
exenatide and sitagliptinPhase 4Peptide1 trial
Insulin PeglisproPhase 32 trials
TirzepatidePhase 3Peptide1 trial
exenatidePhase 3Peptide1 trial
+5 more programs
Active Trials
NCT02669524Completed20Est. Aug 2016
NCT02385084Terminated18Est. May 2015
NCT02217618Completed16Est. Sep 2014
+12 more trials
Bristol Myers Squibb
9 programs
2
2
2
Metformin XRPhase 41 trial
SaxagliptinPhase 4Small Molecule
DapagliflozinPhase 3Small Molecule
DapagliflozinPhase 3Small Molecule
DapagliflozinPhase 1Small Molecule
+4 more programs
Active Trials
NCT02863523Completed139Est. Dec 2017
NCT00778622Completed371Est. Mar 2011
Takeda
TakedaTOKYO, Japan
9 programs
1
2
3
MetforminPhase 41 trial
TrelagliptinPhase 4Small Molecule4 trials
alogliptinPhase 4Small Molecule1 trial
Alogliptin and voglibosePhase 2/31 trial
Alogliptin and voglibosePhase 2/31 trial
+4 more programs
Active Trials
NCT04980014Completed730Est. Aug 2019
NCT03555591Completed3,198Est. Oct 2021
NCT04285983Completed89Est. Jan 2023
+9 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
3 programs
1
1
LinagliptinPhase 3Small Molecule1 trial
EmpagliflozinN/ASmall Molecule1 trial
No TreatmentN/A1 trial
Active Trials
NCT04927858Completed460,558Est. Nov 2018
NCT03064841Completed1,537Est. Dec 2017
NCT02015299Completed45Est. Mar 2016
Novartis
NovartisBASEL, Switzerland
3 programs
1
1
1
vildagliptin/metforminPhase 42 trials
LAF 237Phase 31 trial
interactive videogame Wii Fit PlusPhase 11 trial
Active Trials
NCT01735643Completed220Est. Sep 2012
NCT00230464Completed16Est. Sep 2005
NCT01871558Completed42Est. Feb 2015
+1 more trials
T-Therapeutics
T-TherapeuticsUK - Cambridge
2 programs
2
ExenatidePhase 4Peptide1 trial
Exenatide SCPhase 4Peptide1 trial
Active Trials
NCT00974272CompletedEst. Nov 2008
NCT01181986CompletedEst. Dec 2012
Bayer
BayerLEVERKUSEN, Germany
1 program
1
AcarbosePhase 45 trials
Active Trials
NCT04665570Completed2,000Est. Sep 2024
NCT04065581Completed24Est. Mar 2020
NCT03805191Unknown900Est. Dec 2022
+2 more trials
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
ColesevelamPhase 41 trial
Active Trials
NCT02682680CompletedEst. May 2017
Guerbet
GuerbetFrance - Villepinte
1 program
1
iobitridolPhase 41 trial
Active Trials
NCT01254552Completed351Est. Oct 2016
Insulet
InsuletACTON, MA
4 programs
1
Human regular U-500 insulinPhase 3
Active Comparator: Omnipod M System with lower starting doseN/A1 trial
Omnipod 5 Automated Insulin Delivery SystemN/A1 trial
Omnipod M systemN/A1 trial
Active Trials
NCT07070830CompletedEst. Jan 2026
NCT04617795CompletedEst. Mar 2022
NCT07276776Active Not RecruitingEst. Feb 2026
GS
Gilead SciencesFOSTER CITY, CA
4 programs
2
1
1
RanolazinePhase 31 trial
MBX-102Phase 21 trial
MetforminPhase 11 trial
RanolazinePhase 11 trial
Active Trials
NCT01546558Completed25Est. Mar 2012
NCT01843127Completed24Est. Sep 2013
NCT00814372Terminated242Est. Feb 2010
+1 more trials
Ionis Pharmaceuticals
10 programs
3
7
ISIS 113715Phase 21 trial
ISIS 113715Phase 21 trial
ISIS 113715Phase 21 trial
ISIS 113715Phase 21 trial
ISIS-GCCRRxPhase 21 trial
+5 more programs
Active Trials
NCT00365781Completed10Est. Sep 2006
NCT00519727Completed60Est. Jun 2008
NCT00836225Completed103Est. Jan 2012
+7 more trials
Abbott
AbbottABBOTT PARK, IL
3 programs
2
enteral nutritional formulaPhase 21 trial
standard enteral feeding productPhase 21 trial
MNT according to AND EBNPG for Type 2 DMN/A1 trial
Active Trials
NCT01703611Completed238Est. Dec 2014
NCT00520065Completed33Est. Nov 2007
NCT00544206Completed11Est. Sep 2008
Akros Pharma
1 program
1
JTT-851Phase 21 trial
Active Trials
NCT01699737Completed325Est. Jul 2013
Opko Health
Opko HealthMIAMI, FL
1 program
1
OPK-88003Phase 21 trial
Active Trials
NCT03406377CompletedEst. Jun 2019
Liminal BioSciences
1 program
1
PBI-4050Phase 21 trial
Active Trials
NCT03081598TerminatedEst. Sep 2018
CT
1
TQ-F3083 capsule 10 mgPhase 21 trial
Active Trials
NCT03986073UnknownEst. Sep 2020
Fusion Pharmaceuticals Inc.
1 program
1
BMF-219Phase 1/21 trial
Active Trials
NCT05731544CompletedEst. Jul 2025
Biomea Fusion
Biomea FusionSAN CARLOS, CA
1 program
1
BMF-219Phase 1/2
Pfizer
PfizerNEW YORK, NY
4 programs
4
Ertugliflozin 15 mgPhase 11 trial
PF-04937319 IR MSTPhase 11 trial
PF-04937319 once-dailyPhase 11 trial
Unlabeled ertugliflozin for oral usePhase 11 trial
Active Trials
NCT02115347Completed16Est. Jan 2015
NCT02206607Completed39Est. Jan 2015
NCT01933672Completed33Est. Mar 2014
+1 more trials
HM
Hua MedicineChina - Shanghai
4 programs
4
HMS5552Phase 11 trial
HMS5552Phase 11 trial
HMS5552Phase 11 trial
MetforminPhase 11 trial
Active Trials
NCT04324424Completed17Est. Sep 2019
NCT02077452Completed53Est. Oct 2014
NCT04426708Completed25Est. Jul 2020
+1 more trials
Sciwind Biosciences
Sciwind BiosciencesChina - Hangzhou
2 programs
2
Cohort APhase 11 trial
XW014Phase 11 trial
Active Trials
NCT04389775CompletedEst. Sep 2021
NCT05579314CompletedEst. Nov 2024
Eccogene
EccogeneChina - Shanghai
2 programs
2
ECC5004Phase 11 trial
ECC5004Phase 11 trial
Active Trials
NCT06293742CompletedEst. Apr 2024
NCT06268145CompletedEst. Mar 2024
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
Maridebart cafraglutidePhase 1Peptide1 trial
Active Trials
NCT07160257Recruiting70Est. Dec 2026

+6 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
SanofiInsulin glargine
SanofiInsulin glargine
SanofiInsulin glargine
SanofiInsulin glargine
SanofiInsulin glargine
SanofiInsulin glargine
SanofiInsulin glargine
SanofiInsulin glargine
SanofiInsulin glargine
SanofiInsulin glargine
SanofiInsulin glargine
SanofiInsulin glargine
SanofiInsulin glargine
TakedaTrelagliptin
Astellasmetformin

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 17,482 patients across 50 trials

NCT07307235SanofiInsulin glargine

Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents

Start: Dec 2025Est. completion: Dec 20271,316 patients
Phase 4Not Yet Recruiting
NCT06716424SanofiInsulin glargine

A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus

Start: Jan 2025Est. completion: Jun 2026105 patients
Phase 4Active Not Recruiting
NCT06671587SanofiInsulin glargine

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

Start: Dec 2024Est. completion: Sep 2026678 patients
Phase 4Recruiting
NCT05552859SanofiInsulin glargine

Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment

Start: Dec 2022Est. completion: Aug 202362 patients
Phase 4Terminated
NCT05114590SanofiInsulin glargine

Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus

Start: Jan 2022Est. completion: Apr 2023124 patients
Phase 4Completed
NCT04980027SanofiInsulin glargine

Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs

Start: Jun 2021Est. completion: Dec 2022228 patients
Phase 4Completed
NCT05002933SanofiInsulin glargine

A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period

Start: May 2021Est. completion: Feb 2023570 patients
Phase 4Completed
NCT04075513SanofiInsulin glargine

Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients

Start: Oct 2019Est. completion: Sep 2021343 patients
Phase 4Completed
NCT03760991SanofiInsulin glargine

Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin

Start: Dec 2018Est. completion: Sep 2020372 patients
Phase 4Completed
NCT03406000SanofiInsulin glargine

Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL

Start: Jan 2018Est. completion: Feb 2019170 patients
Phase 4Completed
NCT03359837SanofiInsulin glargine

Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy

Start: Jan 2018Est. completion: Jun 2020384 patients
Phase 4Completed
NCT03389490SanofiInsulin glargine

Toujeo Versus NPH Self-titration Study

Start: Jan 2018Est. completion: May 202050 patients
Phase 4Completed
NCT03260868SanofiInsulin glargine

Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)

Start: Sep 2017Est. completion: Nov 201815 patients
Phase 4Terminated
NCT03231709TakedaTrelagliptin

Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus

Start: Aug 2017Est. completion: Feb 201860 patients
Phase 4Completed

A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria

Start: Apr 2017Est. completion: Dec 201833 patients
Phase 4Terminated
NCT03244241Novo NordiskInsulin Degludec 100 UNT/ML [Tresiba]

Basal-bolus Insulin Therapy Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study

Start: Apr 2017Est. completion: Apr 2018100 patients
Phase 4Unknown
NCT03014479TakedaTrelagliptin

Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus

Start: Feb 2017Est. completion: Oct 2017219 patients
Phase 4Completed
NCT03018938Eli Lilly and CompanyInsulin Analog Mid Mixture

A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus

Start: Feb 2017Est. completion: Jul 2019814 patients
Phase 4Completed
NCT02954692SanofiInsulin glargine

A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey

Start: Nov 2016Est. completion: Dec 2017112 patients
Phase 4Completed
NCT02836704SanofiInsulin glargine

Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)

Start: Sep 2016Est. completion: Apr 2018892 patients
Phase 4Completed
NCT02771093TakedaTrelagliptin

An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus

Start: Sep 2016Est. completion: Apr 201727 patients
Phase 4Completed
NCT02847091Astellasipragliflozin

Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy

Start: Jul 2016Est. completion: Nov 2017103 patients
Phase 4Completed
NCT02791035AstellasOral administration of Ipragliflozin

Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin

Start: Jun 2016Est. completion: Mar 2017100 patients
Phase 4Completed
NCT02738151SanofiInsulin glargine

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Start: May 2016Est. completion: Aug 2017929 patients
Phase 4Completed
NCT02688933SanofiInsulin glargine

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

Start: May 2016Est. completion: Jun 2017638 patients
Phase 4Completed

Randomized Trial Comparing Colesevelam vs. Ezetimibe

Start: Jan 2016Est. completion: May 2017
Phase 4Completed
NCT02967237SanofiInsulin glargine

Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment

Start: Jan 2016Est. completion: Jul 2017136 patients
Phase 4Completed
NCT02967211SanofiInsulin glargine

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin

Start: Dec 2015Est. completion: Oct 2017609 patients
Phase 4Completed
NCT02561130AstraZenecainsulin glargine

Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga

Start: Dec 2015Est. completion: Dec 2018154 patients
Phase 4Completed
NCT02606357SanofiInsulin glargine

Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan

Start: Nov 2015Est. completion: Nov 2017242 patients
Phase 4Completed
NCT02967224SanofiInsulin glargine

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin

Start: Nov 2015Est. completion: Oct 2017705 patients
Phase 4Completed
NCT02545842SanofiInsulin glargine

Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)

Start: Sep 2015Est. completion: Apr 2018947 patients
Phase 4Completed
NCT02537834SanofiTofogliflozin

Tofogliflozin GLP-1 Analogue Combination Trial

Start: Aug 2015Est. completion: Oct 201765 patients
Phase 4Completed
NCT02451137SanofiInsulin glargine

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Start: Jun 2015Est. completion: Aug 20183,304 patients
Phase 4Completed
NCT02291874AstellasIpragliflozin

Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)

Start: Oct 2014Est. completion: Jul 2016100 patients
Phase 4Completed

The Practical Evidence of Antidiabetic Combination Therapy in Korea

Start: Sep 2014Est. completion: Jan 2019216 patients
Phase 4Completed
NCT02200991SanofiInsulin glargine

Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine

Start: Aug 2014Est. completion: Nov 2015136 patients
Phase 4Completed

Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes

Start: May 2014Est. completion: Jun 2016494 patients
Phase 4Completed
NCT02027753SanofiInsulin glargine

Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy

Start: Dec 2013Est. completion: Apr 2015109 patients
Phase 4Completed

Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients

Start: Dec 2012Est. completion: Feb 201411 patients
Phase 4Completed
NCT01234597SanofiInsulin glargine

Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day

Start: Dec 2012Est. completion: Apr 2015219 patients
Phase 4Completed
NCT01630369Sanofiinsulin human

Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes

Start: Feb 2012Est. completion: May 2013552 patients
Phase 4Completed

Adding Liraglutide to High Dose Insulin: Breaking the Cycle

Start: Jan 2012Est. completion: Jun 201671 patients
Phase 4Completed
NCT01461577SanofiINSULIN GLARGINE HOE 901

Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure

Start: Nov 2011Est. completion: Dec 201289 patients
Phase 4Completed

Liraglutide Treatment to Patients With Severe Renal Insufficiency

Start: Sep 2011Est. completion: Oct 201340 patients
Phase 4Completed

Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

Start: Aug 2011Est. completion: Jun 201290 patients
Phase 4Completed
NCT01202474SanofiInsulin glargine

Apidra Children & Adolescents Study

Start: May 2011Est. completion: Oct 2012100 patients
Phase 4Completed
NCT01258075Daiichi SankyoHigh-dose colesevelam

Colesevelam for Children With Type 2 Diabetes

Start: Feb 2011Est. completion: Apr 2020236 patients
Phase 4Completed
NCT01203111SanofiInsulin glargine

Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs

Start: Dec 2010Est. completion: Jul 2012207 patients
Phase 4Completed
NCT01204593SanofiInsulin glargine

baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus

Start: Nov 2010Est. completion: Jan 2013206 patients
Phase 4Completed

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

48 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 17,482 patients
30 companies competing in this space